1-3 of 3
Ofir Wolach
Close
Sort by
Journal Articles

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study

Clinical Trials & Observations
Jessica K. Altman, Tsila Zuckerman, Jamie Koprivnikar, James McCloskey, Vamsi Kota, Michael Keng, Olga Frankfurt, Yasmin Abaza, Dale L. Bixby, Ashkan Emadi, Micah Burch, Bhavana Bhatnagar, Selina M. Luger, Mary-Elizabeth Percival, Ofir Wolach, Michael Craig, Chezi Ganzel, Gail Roboz, Itai Levi, Anna Gourevitch, Liat Flaishon, Shoshi Tessler, Chen Blumberg, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe
Journal: Blood Advances
Blood Adv (2023) 7 (24): 7494–7500.
https://doi.org/10.1182/bloodadvances.2023010943
Published: 2023
Journal Articles

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy

Jurjen Versluis, Manu Pandey, Yael Flamand, J. Erika Haydu, Roger Belizaire, Mark Faber, Rahul S. Vedula, Anne Charles, Kevin M. Copson, Shai Shimony, Alon Rozental, Pavan K. Bendapudi, Ofir Wolach, Elizabeth A. Griffiths, James E. Thompson, Richard M. Stone, Daniel J. DeAngelo, Donna Neuberg, Marlise R. Luskin, Eunice S. Wang, R. Coleman Lindsley
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2835–2846.
https://doi.org/10.1182/bloodadvances.2021006166
Published: 2022
Includes: Supplemental data
Journal Articles

Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study

Clinical Trials & Observations
Moshe Yeshurun, Uri Rozovski, Oren Pasvolsky, Ofir Wolach, Ron Ram, Odelia Amit, Tsila Zuckerman, Anat Pek, Maly Rubinstein, Michal Sela-Navon, Pia Raanani, Liat Shargian-Alon
Journal: Blood Advances
Blood Adv (2020) 4 (16): 3822–3828.
https://doi.org/10.1182/bloodadvances.2020002039
Published: 2020